Gaining momentum, biodexa is advancing two recent acquisitions through the clinic

Cardiff, uk / accesswire / november 21, 2024 / biodexa pharmaceuticals plc (nasdaq:bdrx), an acquisition-focused clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs, has made significant progress in transforming itself from a drug delivery innovator to a therapeutics company with a focus on drugs to fight diabetes and cancer. biodexa's strategy is not based on discovering new medicines; rather it looks to reduce the risk of failure in the clinic by re-purposing molecules with proven safety records for new indications.
BDRX Ratings Summary
BDRX Quant Ranking